-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 27, PeptiDream and Takeda announced the expansion of Shuangfa's exclusive cooperation to develop peptide-conjugated drugs (PDCs) around the central nervous system (CNS) target
PeptiDream and Takeda initially reached an exclusive cooperation license agreement in December 2020.
A major challenge in developing new drugs for neurodegenerative diseases is the ability to deliver drug molecules across the blood-brain barrier to the brain
PeptiDream's proprietary peptide discovery platform system (Peptide Discovery Platform System, PDPS) is an advanced and highly versatile discovery platform that can efficiently produce highly diversified (trillion) non-standard peptide libraries for identification of effectiveness and selection Sexual hit candidates can then be developed into therapies based on peptides, small molecules or peptide-drug conjugate drugs
Note: The original text has been deleted